Determination of the burden of hepatitis C virus infection in Ireland

Epidemiology and Infection

Volumn 140, Issue 8, 2012, Pages 1461-1468

  Thornton, L ^a   Murphy, N ^a   Jones, L ^b   Connell, J ^b   Dooley, S ^b   Gavin, S ^a   Hunter, K ^a   Brennan, A ^a  

^a HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Epidemiology; genotype; hepatitis C; Ireland; prevalence; risk factors; trends

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD TRANSFUSION; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; IRELAND; MALE; PREVALENCE; SEX RATIO;

ADULT; BLOOD TRANSFUSION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IRELAND; MALE; RISK FACTORS; RNA, VIRAL; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; YOUNG ADULT;

EID: 84863916360     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811001920     Document Type: Article

References (31)

1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. Journal of Clinical Pharmacology 2004; 44: 20-29.
2. National Institute for Clinical Excellence. NHS. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology appraisal 75. London: NICE, 2004.
3. European Centre for Disease Prevention and Control. Surveillance and prevention of hepatitis B and C in Europe. Stockholm: ECDC, 2010.
4. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC, 2010.
5. O'Gorman A. Illicit drug use in Dublin. In: Korf DJ, Riper H, eds. Illicit drug use in Europe, Proceedings of the Seventh Annual Conference on Drug Use and Drug Policy, Amsterdam. Amsterdam, 1997.
6. Dean G, et al. Follow up of a cohort of intravenous heroin users in north and south central Dublin and in Dun Laoghaire. Irish Medical Journal 1992; 85: 9-10.
7. Smyth R, et al. Hepatitis C infection among injecting drug users attending the National Drug Treatment Centre. Irish Journal of Medical Science 1995; 164: 267-268.
8. Smyth BP, Keenan E, O'Connor JJ. Bloodborne viral infection in Irish injecting drug users. Addiction 1998; 93: 1649-1656.
9. Smyth BP, Keenan E, O'Connor JJ. Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among shortterm injecting drug users. Journal of Epidemiology and Community Health 1999; 53: 434-435.
10. Allwright S, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. British Medical Journal 2000; 321: 78-82.
11. Long J, et al. Prevalence of antibodies to hepatitis B, hepatitis C and HIV and risk factors in entrants to Irish prisons: a national cross-sectional survey. British Medical Journal 2001; 323: 1209-1213.
12. Fitzgerald M, et al. Blood-borne infections in Dublin's opiate users. Irish Journal of Medical Science 2001; 170: 32-34.
13. Grogan L, et al. Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunisation uptake. Irish Journal of Medical Science 2005; 174: 14-20.
14. Cullen W, et al. Hepatitis C infection among drug users attending general practice. Irish Journal of Medical Science 2003; 172: 123-127.
15. Cullen W, et al. Management of hepatitis C among drug users attending general practice in Ireland: Baseline data from the Dublin area hepatitis C in general practice initiative. European Journal of General Practice 2007; 13: 5-12.
16. Comiskey C, Cox G. Research outcome study in Ireland. Evaluating drug treatment effectiveness. Baseline data report, September 2007. Dublin: National Advisory Committee on Drugs, 2007 (. ie/rosie/documents/BaselineReport.pdf). Accessed 31 January 2011.
17. Kelly A, Teljeur C, Carvalho M. Prevalence of opiate use in Ireland 2006: a 3-source capture recapture study. Dublin: National Advisory Committee on Drugs, 2009.
18. Health Protection Surveillance Centre. National hepatitis C database for infection acquired through blood and blood products: Baseline report 2007 (http:// www.hpsc.ie/hpsc/A-Z/HepatitisHIVAIDSandSTIs/ HepatitisC/ HepatitisCDatabase/BaselineandFollowupReports/). Accessed 15 April 2011.
19. Infectious Diseases (Amendment) (no. 3) Regulations 2003. S.I. No. 707 of 2003. Dublin: Stationery Office, 2003.
20. McLeod A, et al. Surveillance of known hepatitis C antibody positive cases in Scotland: Results to 30 September 2008. HPS Weekly Report, 18 February 2009; 43(2009/07): 79-86.
21. Hutchinson SJ, et al. Hepatitis C virus infection in Scotland: Epidemiological review and public health challenges. Scottish Medical Journal 2006; 51: 8-15.
22. Department of Health, United Kingdom. Hepatitis C: Action plan for England. London: Department of Health, 2004.
23. Health Protection Surveillance Centre. Hepatitis C notifications, quarterly reports and annual reports (http:// www.hpsc.ie/hpsc/A-Z/ HepatitisHIVAIDSandSTIs/ HepatitisC/EpidemiologicalData). Accessed 15 April 2011.
24. Duberg A, et al. The epidemiology of hepatitis C virus infection in Sweden. Eurosurveillance 2008; 13: pii=18882.
25. Department of Jobs, Enterprise and Innovation (http:// www.djei.ie). Accessed 8 August 2011.
26. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet 2005; 5: 558-567.
27. Office of the Refugee Applications Commissioner (http:// www.orac.ie). Accessed 8 August 2011.
28. Health Protection Surveillance Centre. National hepatitis C database for infection acquired through blood and blood products, 2010 Report (. ie/hpsc/A-Z/HepatitisHIVAIDSandSTIs/HepatitisC/ HepatitisCDatabase/ BaselineandFollow-upReports/). Accessed 15 April 2011.
29. Ryder N, et al. Prevalence of problem alcohol use among patients attending primary care for methadone treatment. BMC Family Practice 2009; 10: 42.
30. Alcohol and Drug Research Unit. Treated problem drug use in Ireland: figures for 2008 from the National Drug Treatment Reporting System. Dublin: Health Research Board, 2010 (www.drugsandalcohol.ie/ 12771). Accessed 31 January 2011.
31. National Institutes of Health. NIH consensus statement on management of hepatitis C, 10-12 June 2002; 19: 1-46. Bethesda, MD: National Institutes of Health, 2002.